Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCRX NASDAQ:BLUE NASDAQ:NK NASDAQ:RUBY NASDAQ:SRNE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCRXBioCryst Pharmaceuticals$8.88-2.0%$10.08$6.02▼$11.31$1.90B1.043.03 million shs2.20 million shsBLUEbluebird bio$4.97$4.76$3.20▼$28.60$48.67M0.27445,958 shsN/ANKNantKwest$2.87+2.9%$28.01$2.52▼$45.42$313.82M2.611.57 million shs5.28 million shsRUBYRubius Therapeutics$0.06$0.04$0.00▼$0.38$5.16M2.591.15 million shs755,858 shsSRNESorrento Therapeutics$0.00-7.1%$0.00$0.00▼$0.02$772K0.9892,332 shs99,888 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCRXBioCryst Pharmaceuticals-1.99%-0.73%-19.35%+30.21%+36.83%BLUEbluebird bio0.00%0.00%0.00%-3.50%-76.11%NKNantKwest+2.95%+5.68%-18.90%+13.41%-57.08%RUBYRubius Therapeutics0.00%0.00%0.00%0.00%0.00%SRNESorrento Therapeutics-7.14%0.00%-38.10%+30.00%-88.18%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCRXBioCryst Pharmaceuticals4.4971 of 5 stars4.52.00.04.22.01.70.6BLUEbluebird bio2.1789 of 5 stars3.10.00.00.01.41.71.3NKNantKwestN/AN/AN/AN/AN/AN/AN/AN/ARUBYRubius TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ASRNESorrento Therapeutics0.7455 of 5 stars0.02.00.04.30.00.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCRXBioCryst Pharmaceuticals 2.90Moderate Buy$16.7088.06% UpsideBLUEbluebird bio 2.25Hold$44.60797.38% UpsideNKNantKwest 0.00N/AN/AN/ARUBYRubius Therapeutics 0.00N/AN/AN/ASRNESorrento Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest BCRX, BLUE, NK, RUBY, and SRNE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/1/2025BCRXBioCryst PharmaceuticalsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$13.00 ➝ $15.006/30/2025BCRXBioCryst PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$13.006/30/2025BCRXBioCryst PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$16.00 ➝ $18.006/25/2025BCRXBioCryst PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.005/7/2025BCRXBioCryst PharmaceuticalsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$8.00 ➝ $11.005/6/2025BCRXBioCryst PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$11.00 ➝ $13.005/6/2025BCRXBioCryst PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$10.00 ➝ $13.005/6/2025BCRXBioCryst PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$15.00 ➝ $17.005/6/2025BCRXBioCryst PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.004/29/2025BCRXBioCryst PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$20.00(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCRXBioCryst Pharmaceuticals$450.71M4.12N/AN/A($2.30) per share-3.86BLUEbluebird bio$103.95M0.47N/AN/A$35.59 per share0.14NKNantKwest$40K7,845.50N/AN/A$1.23 per share2.33RUBYRubius TherapeuticsN/AN/AN/AN/A$0.17 per shareN/ASRNESorrento Therapeutics$60.32M0.01N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCRXBioCryst Pharmaceuticals-$88.88M-$0.26N/AN/A2.59-10.62%N/A-11.06%8/4/2025 (Estimated)BLUEbluebird bio-$211.91M-$41.32N/AN/AN/A-565.74%-322.46%-53.17%8/12/2025 (Estimated)NKNantKwest-$65.79M-$0.70N/AN/AN/A-76,658.58%-56.06%-46.93%N/ARUBYRubius Therapeutics-$179.67MN/A0.00∞N/AN/AN/AN/AN/ASRNESorrento Therapeutics-$572.84MN/A0.00∞N/AN/AN/AN/AN/ALatest BCRX, BLUE, NK, RUBY, and SRNE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/4/2025Q2 2025BCRXBioCryst Pharmaceuticals$0.02N/AN/AN/A$149.59 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCRXBioCryst PharmaceuticalsN/AN/AN/AN/AN/ABLUEbluebird bioN/AN/AN/AN/AN/ANKNantKwestN/AN/AN/AN/AN/ARUBYRubius TherapeuticsN/AN/AN/AN/AN/ASRNESorrento TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCRXBioCryst PharmaceuticalsN/A2.932.88BLUEbluebird bio0.370.510.33NKNantKwestN/A4.744.74RUBYRubius TherapeuticsN/AN/AN/ASRNESorrento TherapeuticsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCRXBioCryst Pharmaceuticals85.88%BLUEbluebird bio87.43%NKNantKwest9.38%RUBYRubius TherapeuticsN/ASRNESorrento Therapeutics0.02%Insider OwnershipCompanyInsider OwnershipBCRXBioCryst Pharmaceuticals4.80%BLUEbluebird bio1.40%NKNantKwest71.73%RUBYRubius Therapeutics5.30%SRNESorrento Therapeutics2.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCRXBioCryst Pharmaceuticals530209.25 million199.21 millionOptionableBLUEbluebird bio5209.79 million9.59 millionOptionableNKNantKwest160109.35 millionN/ANot OptionableRUBYRubius Therapeutics690.48 million85.69 millionNot OptionableSRNESorrento Therapeutics800551.28 million536.95 millionNo DataBCRX, BLUE, NK, RUBY, and SRNE HeadlinesRecent News About These CompaniesSorrento Therapeutics Inc (SRNE) - Investing.comJuly 3, 2025 | investing.comSRNE Sorrento Therapeutics, Inc. - Seeking AlphaJune 29, 2025 | seekingalpha.comSorrento Therapeutics Stock Price, Quotes and Forecasts | OTC:SRNE | BenzingaApril 19, 2025 | benzinga.comSorrento Shareholders Lose Discovery Bid Over Judge RelationshipMarch 28, 2025 | news.bloomberglaw.comNScilex says bankruptcy court extends lockup period on shares of Scilex dividendJanuary 31, 2025 | markets.businessinsider.comDSI Introduces Westbury Sorrento Aluminum Railing with Bold Distinctive Mesh Stainless Steel InfillsOctober 24, 2024 | newsfilecorp.comNSorrento enrols 60 of 80-patient Phase II target for abivertinib in Covid-19; futility analysis potentially in a month, CEO saysAugust 20, 2024 | msn.comSorrento Resources to Sell Three Newfoundland Properties to Gold HunterMay 29, 2024 | newsfilecorp.comNSorrento Therapeutics Inc (SRNE)May 25, 2024 | investing.comSorrento Resources Announces Appointment of Alex Bugden as a Director and Qualified PersonMay 8, 2024 | newsfilecorp.comNDSI Introduces Westbury(R) Sorrento Aluminum and Stainless Steel Mesh RailingMay 1, 2024 | newsfilecorp.comNSorrento Therapeutics Inc SRNEApril 26, 2024 | morningstar.comMSorrento Therapeutics Wins Appeal Over Covid Treatment RemarksMarch 27, 2024 | news.bloomberglaw.comNSorrento Therapeutics Wins Appeal Over Covid Treatment RemarksMarch 27, 2024 | news.bloomberglaw.comNSorrento Defeats DOJ Effort to Move Bankruptcy Out of Texas (1)March 12, 2024 | news.bloomberglaw.comNJudge Declines to Dismiss Sorrento Therapeutics Bankruptcy CaseMarch 12, 2024 | wsj.comVirpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.February 27, 2024 | tmcnet.comVirpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.February 27, 2024 | businesswire.comSorrento TherapeuticsFebruary 7, 2024 | pharmaphorum.comP5 Sanders Cove, Sorrento WA 6020January 18, 2024 | domain.com.auDNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeTop 3 Bank Stocks to Watch as Fed Rate Cuts LoomBy Chris Markoch | June 25, 2025View Top 3 Bank Stocks to Watch as Fed Rate Cuts LoomBig Bank Buybacks: Morgan Stanley, Citi, & Wells Fargo LeadBy Gabriel Osorio-Mazilli | July 3, 2025View Big Bank Buybacks: Morgan Stanley, Citi, & Wells Fargo LeadDon’t Miss Out: 3 Blue-Chips Set to Pop This Earnings SeasonBy Chris Markoch | July 8, 2025View Don’t Miss Out: 3 Blue-Chips Set to Pop This Earnings SeasonAeva & Mobileye: LiDAR Stocks Powering the Autonomous RevolutionBy Dan Schmidt | July 2, 2025View Aeva & Mobileye: LiDAR Stocks Powering the Autonomous RevolutionBCRX, BLUE, NK, RUBY, and SRNE Company DescriptionsBioCryst Pharmaceuticals NASDAQ:BCRX$8.88 -0.18 (-1.99%) Closing price 07/10/2025 04:00 PM EasternExtended Trading$8.82 -0.06 (-0.62%) As of 06:21 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.bluebird bio NASDAQ:BLUE$4.97 0.00 (0.00%) As of 06/2/2025bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.NantKwest NASDAQ:NKNantKwest, Inc., a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and Nant cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells. It is also developing high-affinity natural killer (haNK) product candidates primarily for the treatment of various cancers; and tank and t-haNK product candidates to treat solid tumors. NantKwest, Inc. has a co-development agreement with Altor BioScience, LLC to collaborate on the development of therapeutic applications combining the company's proprietary natural killer cells with Altor's N-801 and/or N-803 products; collaboration with Be The Match BioTherapies for the development of cell therapy to prevent COVID-19 deaths; and strategic alliance with Immunitybio. It also has a collaboration with CBR Systems, Inc. to develop a COVID-19 treatment leveraging newborn stem cells. The company was formerly known as Conkwest, Inc. and changed its name to NantKwest, Inc. in July 2015. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California.Rubius Therapeutics NASDAQ:RUBYRubius Therapeutics, Inc., a biopharmaceutical company, focuses on the development of red cell therapeutics for the treatment of cancer and autoimmune diseases. The company was formerly known as VL26, Inc and as changed its name to Rubius Therapeutics, Inc. in 2015. Rubius Therapeutics, Inc. was incorporated in 2013 and is based in Foxborough, Massachusetts.Sorrento Therapeutics NASDAQ:SRNE$0.0013 0.00 (-7.14%) As of 07/10/2025 03:52 PM EasternSorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis pain treatment; and ZTlido, a lidocaine topical system for the treatment of post-herpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Group: Up 385%, Analysts Say It’s Still a Bargain BigBear.ai: Why a 90% Rally Could Be Just the Start Will Oracle's Cloud and AI Deals Propel It to New Highs? Enovix Shares Hit 6-Month High; Long-Term Highs to Follow Tesla Stock Could Accelerate on New EV Tax Legislation SoundHound Rises as Short Sellers Exit and AI Demand Grows Alphabet: Technical Momentum Is Starting to Turn Boeing's Rebound Is Well Underway—But Is It Too Late? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
